This has been observed that will the US-based Novavax possesses begun trials in mankind and the EMA may evaluate data from these types of studies and other medical trials.
In addition, EMA also evaluated the BioNTech, Moderna and AstraZeneca vaccines it had previously authorized, along with the approval process has been designed in a short time period when these companies requested approval in the European Union.
At the stop of January, Novavax introduced an average of ninety days percent success in Period 3 vaccine studies around the UK.
The European Union has completed original negotiations with Novavax around the purchase of 200 thousand doses of vaccine, merely the parties are virtually not with the stage involving signing the contract.
Does the vaccine work properly?
The vaccine designed by Novavax is protein-based, in the form involving other vaccines, possesses little molecules made from the laboratory-developed version of this protein called “spike” upon the surface of SARS-CoV-2. In addition, the vaccine contains a supplement that will strengthens the body’s immune system response.
In this vaccine, the immune method perceives protein particles like foreign and produces healthy defense tools in this form of antibodies plus T cells. If this vaccinated person then will come into contact with SARS-CoV-2, the immune system understands the barbed protein within the virus and attacks that protein.
Antibodies and immune system cells work together from the virus to secure against Covid-19 disease which will help prevent the virus from coming into cells and destroying contaminated cells.
